Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02388295 · ClinicalTrials.gov registry record · Phase 2
AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients
A Phase 2 study of Multiple System Atrophy (MSA), sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
- 17
- Study locations
NCT02388295: Completed Phase 2 study of Multiple System Atrophy (MSA), sponsored by AstraZeneca.
NCT02388295 is a Phase 2 study of Multiple System Atrophy (MSA) that has completed, run by AstraZeneca. The registered enrollment target is 59 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower). The trial reports 17 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02388295, a Phase 2 study of Multiple System Atrophy (MSA), has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
- 17
- Study locations
Study Summary
AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.
Primary Outcome
Striatum Brain region: Change from baseline in microglia activation via PET By \[11C\]PBR28 binding to translocator protein
Conditions Studied
Interventions
- DRUG Placebo
- DRUG AZD3241
Study Locations (17)
Other
- Research Site - Innsbruck
- Research Site - Turku
- Research Site - Bordeaux
- Research Site - Toulouse
- Research Site - Salerno
- Research Site - Stockholm
- Research Site - London
- Research Site - London
- Research Site - Oxford
New York
- Research Site - New York
- Research Site - New York
California
- Research Site - Stanford
Connecticut
- Research Site - New Haven
Florida
- Research Site - Tampa
Massachusetts
- Research Site - Boston
Michigan
- Research Site - Ann Arbor
Minnesota
- Research Site - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2015-04-27 |
| Est. Completion | 2016-09-19 |
| Phase | Phase 2 |
What the finished NCT02388295 record still lists
NCT02388295 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 59 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (56% lower).
The record links to 1 condition, with Multiple System Atrophy (MSA) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02388295 lists 17 locations in 8 states (Other, New York, California).
Frequently Asked Questions
What is clinical trial NCT02388295 about?
NCT02388295 is a clinical study titled "AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients". AZD3241 myeloperoxidase (MPO) inhibitor trial is assessing safety and tolerability, randomized trial, in patients with Multiple System Atrophy.
What is the current status of trial NCT02388295?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2015-04-27. Estimated completion is 2016-09-19.
What conditions does trial NCT02388295 study?
This clinical trial studies the following conditions: Multiple System Atrophy (MSA).
What interventions are being tested in trial NCT02388295?
The interventions under investigation include: Placebo (DRUG), AZD3241 (DRUG).
Who is sponsoring clinical trial NCT02388295?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02388295 being conducted?
This trial has 17 study locations across California, Connecticut, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple System Atrophy (MSA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02388295's enrollment target sits among peer trials
59 1133rd of 2000 higher than 866 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03801083 · 59 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers
- NCT04332367 · 59 participants · Phase 2
Carboplatin, Taxane And Ramucirumab for Patients With NSCLC After Pemetrexed or Pembrolizumab Maintenance
- NCT05489575 · 59 participants · NA
CPAP for the Treatment of Supine Hypertension
- NCT06721689 · 59 participants · Phase 1
PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI